Top

Published in:

Open Access 01-12-2010 | NON-THEMATIC REVIEW

Cytochrome P450-derived eicosanoids: the neglected pathway in cancer

Authors: Dipak Panigrahy, Arja Kaipainen, Emily R. Greene, Sui Huang

Published in: Cancer and Metastasis Reviews | Issue 4/2010

Abstract

Endogenously produced lipid autacoids are locally acting small molecule mediators that play a central role in the regulation of inflammation and tissue homeostasis. A well-studied group of autacoids are the products of arachidonic acid metabolism, among which the prostaglandins and leukotrienes are the best known. They are generated by two pathways controlled by the enzyme systems cyclooxygenase and lipoxygenase, respectively. However, arachidonic acid is also substrate for a third enzymatic pathway, the cytochrome P450 (CYP) system. This third eicosanoid pathway consists of two main branches: ω-hydroxylases convert arachidonic acid to hydroxyeicosatetraenoic acids (HETEs) and epoxygenases convert it to epoxyeicosatrienoic acids (EETs). This third CYP pathway was originally studied in conjunction with inflammatory and cardiovascular disease. Arachidonic acid and its metabolites have recently stimulated great interest in cancer biology; but, unlike prostaglandins and leukotrienes the link between cytochome P450 metabolites and cancer has received little attention. In this review, the emerging role in cancer of cytochrome P450 metabolites, notably 20-HETE and EETs, are discussed.

Zeldin, D. C. (2001). Epoxygenase pathways of arachidonic acid metabolism. The Journal of Biological Chemistry, 276, 36059–36062.PubMed

Imig, J. D., & Hammock, B. D. (2009). Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nature Reviews. Drug Discovery, 8, 794–805.PubMed

Wang, D., & Dubois, R. N. (2010). Eicosanoids and cancer. Nature Reviews. Cancer, 10, 181–193.PubMed

Roman, R. J. (2002). P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiological Reviews, 82, 131–185.PubMed

Fleming, I. (2007). Epoxyeicosatrienoic acids, cell signaling and angiogenesis. Prostaglandins & Other Lipid Mediators, 82, 60–67.

Spector, A. A., & Norris, A. W. (2007). Action of epoxyeicosatrienoic acids on cellular function. American Journal of Physiology. Cell Physiology, 292, C996–C1012.PubMed

Hardwick, J. P., Song, B. J., Huberman, E., & Gonzalez, F. J. (1987). Isolation, complementary DNA sequence, and regulation of rat hepatic lauric acid omega-hydroxylase (cytochrome P-450LA omega). Identification of a new cytochrome P-450 gene family. The Journal of Biological Chemistry, 262, 801–810.PubMed

Powell, P. K., Wolf, I., Jin, R., & Lasker, J. M. (1998). Metabolism of arachidonic acid to 20-hydroxy-5, 8, 11, 14-eicosatetraenoic acid by P450 enzymes in human liver: Involvement of CYP4F2 and CYP4A11. The Journal of Pharmacology and Experimental Therapeutics, 285, 1327–1336.PubMed

Miyata, N., & Roman, R. J. (2005). Role of 20-hydroxyeicosatetraenoic acid (20-HETE) in vascular system. Journal of Smooth Muscle Research, 41, 175–193.PubMed

10.

Fisslthaler, B., Popp, R., Kiss, L., Potente, M., Harder, D. R., et al. (1999). Cytochrome P450 2 C is an EDHF synthase in coronary arteries. Nature, 401, 493–497.PubMed

11.

Kaspera, R., & Totah, R. A. (2009). Epoxyeicosatrienoic acids: Formation, metabolism and potential role in tissue physiology and pathophysiology. Expert Opinion on Drug Metabolism & Toxicology, 5, 757–771.

12.

Zeldin, D. C., Kobayashi, J., Falck, J. R., Winder, B. S., Hammock, B. D., et al. (1993). Regio- and enantiofacial selectivity of epoxyeicosatrienoic acid hydration by cytosolic epoxide hydrolase. The Journal of Biological Chemistry, 268, 6402–6407.PubMed

13.

Yu, Z., Xu, F., Huse, L. M., Morisseau, C., Draper, A. J., et al. (2000). Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circulation Research, 87, 992–998.PubMed

14.

Chacos, N., Capdevila, J., Falck, J. R., Manna, S., Martin-Wixtrom, C., et al. (1983). The reaction of arachidonic acid epoxides (epoxyeicosatrienoic acids) with a cytosolic epoxide hydrolase. Archives of Biochemistry and Biophysics, 223, 639–648.PubMed

15.

Capdevila, J. H., Harris, R. C., & Falck, J. R. (2002). Microsomal cytochrome P450 and eicosanoid metabolism. Cellular and Molecular Life Sciences, 59, 780–789.PubMed

16.

Capdevila, J., Chacos, N., Werringloer, J., Prough, R. A., & Estabrook, R. W. (1981). Liver microsomal cytochrome P-450 and the oxidative metabolism of arachidonic acid. Proceedings of the National Academy of Sciences of the United States of America, 78, 5362–5366.PubMed

17.

Capdevila, J., Marnett, L. J., Chacos, N., Prough, R. A., & Estabrook, R. W. (1982). Cytochrome P-450-dependent oxygenation of arachidonic acid to hydroxyicosatetraenoic acids. Proceedings of the National Academy of Sciences of the United States of America, 79, 767–770.PubMed

18.

Morrison, A. R., & Pascoe, N. (1981). Metabolism of arachidonate through NADPH-dependent oxygenase of renal cortex. Proceedings of the National Academy of Sciences of the United States of America, 78, 7375–7378.PubMed

19.

Oliw, E. H., Lawson, J. A., Brash, A. R., & Oates, J. A. (1981). Arachidonic acid metabolism in rabbit renal cortex. Formation of two novel dihydroxyeicosatrienoic acids. The Journal of Biological Chemistry, 256, 9924–9931.PubMed

20.

Campbell, W. B., Gebremedhin, D., Pratt, P. F., & Harder, D. R. (1996). Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circulation Research, 78, 415–423.PubMed

21.

Morisseau, C., Goodrow, M. H., Dowdy, D., Zheng, J., Greene, J. F., et al. (1999). Potent urea and carbamate inhibitors of soluble epoxide hydrolases. Proceedings of the National Academy of Sciences of the United States of America, 96, 8849–8854.PubMed

22.

Newman, J. W., Watanabe, T., & Hammock, B. D. (2002). The simultaneous quantification of cytochrome P450 dependent linoleate and arachidonate metabolites in urine by HPLC-MS/MS. Journal of Lipid Research, 43, 1563–1578.PubMed

23.

Nelson, D. R., Zeldin, D. C., Hoffman, S. M., Maltais, L. J., Wain, H. M., et al. (2004). Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics, 14, 1–18.PubMed

24.

Nebert, D. W., & Russell, D. W. (2002). Clinical importance of the cytochromes P450. Lancet, 360, 1155–1162.PubMed

25.

Wang, H., Zhao, Y., Bradbury, J. A., Graves, J. P., Foley, J., et al. (2004). Cloning, expression, and characterization of three new mouse cytochrome p450 enzymes and partial characterization of their fatty acid oxidation activities. Molecular Pharmacology, 65, 1148–1158.PubMed

26.

Finta, C., & Zaphiropoulos, P. G. (2000). The human CYP2C locus: A prototype for intergenic and exon repetition splicing events. Genomics, 63, 433–438.PubMed

27.

Waxman, D. J., Chen, L., Hecht, J. E., & Jounaidi, Y. (1999). Cytochrome P450-based cancer gene therapy: Recent advances and future prospects. Drug Metabolism Reviews, 31, 503–522.PubMed

28.

Nebert, D. W., & Dalton, T. P. (2006). The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis. Nature Reviews. Cancer, 6, 947–960.PubMed

29.

Swanson, H. I., Njar, V. C., Yu, Z., Castro, D. J., Gonzalez, F. J., et al. (2010). Targeting drug-metabolizing enzymes for effective chemoprevention and chemotherapy. Drug Metabolism and Disposition, 38, 539–544.PubMed

30.

Lu, H., Chen, C. S., & Waxman, D. J. (2009). Potentiation of methoxymorpholinyl doxorubicin antitumor activity by P450 3A4 gene transfer. Cancer Gene Therapy, 16, 393–404.PubMed

31.

Jordan, V. C., & Brodie, A. M. (2007). Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids, 72, 7–25.PubMed

32.

Bruno, R. D., & Njar, V. C. (2007). Targeting cytochrome P450 enzymes: A new approach in anti-cancer drug development. Bioorganic & Medicinal Chemistry, 15, 5047–5060.

33.

Moreira, V. M., Salvador, J. A., Vasaitis, T. S., & Njar, V. C. (2008). CYP17 inhibitors for prostate cancer treatment—An update. Current Medicinal Chemistry, 15, 868–899.PubMed

34.

Node, K., Huo, Y., Ruan, X., Yang, B., Spiecker, M., et al. (1999). Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science, 285, 1276–1279.PubMed

35.

Rosolowsky, M., & Campbell, W. B. (1996). Synthesis of hydroxyeicosatetraenoic (HETEs) and epoxyeicosatrienoic acids (EETs) by cultured bovine coronary artery endothelial cells. Biochimica et Biophysica Acta, 1299, 267–277.PubMed

36.

Pozzi, A., Macias-Perez, I., Abair, T., Wei, S., Su, Y., et al. (2005). Characterization of 5, 6- and 8, 9-epoxyeicosatrienoic acids (5, 6- and 8, 9-EET) as potent in vivo angiogenic lipids. The Journal of Biological Chemistry, 280, 27138–27146.PubMed

37.

Fleming, I. (2007). DiscrEET regulators of homeostasis: Epoxyeicosatrienoic acids, cytochrome P450 epoxygenases and vascular inflammation. Trends in Pharmacological Sciences, 28, 448–452.PubMed

38.

Alkayed, N. J., Narayanan, J., Gebremedhin, D., Medhora, M., Roman, R. J., et al. (1996). Molecular characterization of an arachidonic acid epoxygenase in rat brain astrocytes. Stroke, 27, 971–979.PubMed

39.

Amruthesh, S. C., Boerschel, M. F., McKinney, J. S., Willoughby, K. A., & Ellis, E. F. (1993). Metabolism of arachidonic acid to epoxyeicosatrienoic acids, hydroxyeicosatetraenoic acids, and prostaglandins in cultured rat hippocampal astrocytes. Journal of Neurochemistry, 61, 150–159.PubMed

40.

Munzenmaier, D. H., & Harder, D. R. (2000). Cerebral microvascular endothelial cell tube formation: Role of astrocytic epoxyeicosatrienoic acid release. American Journal of Physiology. Heart and Circulatory Physiology, 278, H1163–H1167.PubMed

41.

Wu, S., Moomaw, C. R., Tomer, K. B., Falck, J. R., & Zeldin, D. C. (1996). Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. The Journal of Biological Chemistry, 271, 3460–3468.PubMed

42.

Wu, S., Chen, W., Murphy, E., Gabel, S., Tomer, K. B., et al. (1997). Molecular cloning, expression, and functional significance of a cytochrome P450 highly expressed in rat heart myocytes. The Journal of Biological Chemistry, 272, 12551–12559.PubMed

43.

Nakayama, K., Nitto, T., Inoue, T., & Node, K. (2008). Expression of the cytochrome P450 epoxygenase CYP2J2 in human monocytic leukocytes. Life Sciences, 83, 339–345.PubMed

44.

Nieves, D., & Moreno, J. J. (2006). Hydroxyeicosatetraenoic acids released through the cytochrome P-450 pathway regulate 3 T6 fibroblast growth. Journal of Lipid Research, 47, 2681–2689.PubMed

45.

Muthalif, M. M., Benter, I. F., Karzoun, N., Fatima, S., Harper, J., et al. (1998). 20-Hydroxyeicosatetraenoic acid mediates calcium/calmodulin-dependent protein kinase II-induced mitogen-activated protein kinase activation in vascular smooth muscle cells. Proceedings of the National Academy of Sciences of the United States of America, 95, 12701–12706.PubMed

46.

Schwartzman, M. L., Falck, J. R., Yadagiri, P., & Escalante, B. (1989). Metabolism of 20-hydroxyeicosatetraenoic acid by cyclooxygenase. Formation and identification of novel endothelium-dependent vasoconstrictor metabolites. The Journal of Biological Chemistry, 264, 11658–11662.PubMed

47.

Kaduce, T. L., Fang, X., Harmon, S. D., Oltman, C. L., Dellsperger, K. C., et al. (2004). 20-hydroxyeicosatetraenoic acid (20-HETE) metabolism in coronary endothelial cells. The Journal of Biological Chemistry, 279, 2648–2656.PubMed

48.

Moreno, J. J. (2009). New aspects of the role of hydroxyeicosatetraenoic acids in cell growth and cancer development. Biochemical Pharmacology, 77, 1–10.PubMed

49.

Stark, K., Dostalek, M., & Guengerich, F. P. (2008). Expression and purification of orphan cytochrome P450 4×1 and oxidation of anandamide. The FEBS Journal, 275, 3706–3717.PubMed

50.

Chuang, S. S., Helvig, C., Taimi, M., Ramshaw, H. A., Collop, A. H., et al. (2004). CYP2U1, a novel human thymus- and brain-specific cytochrome P450, catalyzes omega- and (omega-1)-hydroxylation of fatty acids. The Journal of Biological Chemistry, 279, 6305–6314.PubMed

51.

Yang, W., Holmes, B. B., Gopal, V. R., Kishore, R. V., Sangras, B., et al. (2007). Characterization of 14, 15-epoxyeicosatrienoyl-sulfonamides as 14, 15-epoxyeicosatrienoic acid agonists: Use for studies of metabolism and ligand binding. The Journal of Pharmacology and Experimental Therapeutics, 321, 1023–1031.PubMed

52.

Spector, A. A. (2009). Arachidonic acid cytochrome P450 epoxygenase pathway. Journal of Lipid Research, 50(Suppl), S52–S56.PubMed

53.

Karara, A., Wei, S., Spady, D., Swift, L., Capdevila, J. H., et al. (1992). Arachidonic acid epoxygenase: Structural characterization and quantification of epoxyeicosatrienoates in plasma. Biochemical and Biophysical Research Communications, 182, 1320–1325.PubMed

54.

Spector, A. A., Fang, X., Snyder, G. D., & Weintraub, N. L. (2004). Epoxyeicosatrienoic acids (EETs): Metabolism and biochemical function. Progress in Lipid Research, 43, 55–90.PubMed

55.

Widstrom, R. L., Norris, A. W., Van Der Veer, J., & Spector, A. A. (2003). Fatty acid-binding proteins inhibit hydration of epoxyeicosatrienoic acids by soluble epoxide hydrolase. Biochemistry, 42, 11762–11767.PubMed

56.

Liu, Y., Zhang, Y., Schmelzer, K., Lee, T. S., Fang, X., et al. (2005). The antiinflammatory effect of laminar flow: The role of PPARgamma, epoxyeicosatrienoic acids, and soluble epoxide hydrolase. Proceedings of the National Academy of Sciences of the United States of America, 102, 16747–16752.PubMed

57.

Deng, Y., Theken, K. N., & Lee, C. R. (2010). Cytochrome P450 epoxygenases, soluble epoxide hydrolase, and the regulation of cardiovascular inflammation. Journal of Molecular and Cellular Cardiology, 48, 331–341.PubMed

58.

Cowart, L. A., Wei, S., Hsu, M. H., Johnson, E. F., Krishna, M. U., et al. (2002). The CYP4A isoforms hydroxylate epoxyeicosatrienoic acids to form high affinity peroxisome proliferator-activated receptor ligands. The Journal of Biological Chemistry, 277, 35105–35112.PubMed

59.

Fang, X., Hu, S., Watanabe, T., Weintraub, N. L., Snyder, G. D., et al. (2005). Activation of peroxisome proliferator-activated receptor alpha by substituted urea-derived soluble epoxide hydrolase inhibitors. The Journal of Pharmacology and Experimental Therapeutics, 314, 260–270.PubMed

60.

Fang, X., Hu, S., Xu, B., Snyder, G. D., Harmon, S., et al. (2006). 14, 15-Dihydroxyeicosatrienoic acid activates peroxisome proliferator-activated receptor-alpha. American Journal of Physiology. Heart and Circulatory Physiology, 290, H55–H63.PubMed

61.

Folkman, J. (1990). What is the evidence that tumors are angiogenesis-dependent? Journal of the National Cancer Institute, 82, 4–6.PubMed

62.

McAllister, S. S., & Weinberg, R. A. (2010). Tumor-host interactions: A far-reaching relationship. Journal of Clinical Oncology, 28, 4022–4028.PubMed

63.

Panigrahy, D., Huang, S., Kieran, M. W., & Kaipainen, A. (2005). PPARgamma as a therapeutic target for tumor angiogenesis and metastasis. Cancer Biology & Therapy, 4, 687–693.

64.

Bhowmick, N. A., Neilson, E. G., & Moses, H. L. (2004). Stromal fibroblasts in cancer initiation and progression. Nature, 432, 332–337.PubMed

65.

Folkman, J. (1971). Tumor angiogenesis: Therapeutic implications. The New England Journal of Medicine, 285, 1182–1186.PubMed

66.

Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., et al. (2005). Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell, 121, 335–348.PubMed

67.

Joyce, J. A., & Pollard, J. W. (2009). Microenvironmental regulation of metastasis. Nature Reviews. Cancer, 9, 239–252.PubMed

68.

Lin, E. Y., & Pollard, J. W. (2004). Role of infiltrated leucocytes in tumour growth and spread. British Journal of Cancer, 90, 2053–2058.PubMed

69.

de Visser, K. E., Eichten, A., & Coussens, L. M. (2006). Paradoxical roles of the immune system during cancer development. Nature Reviews. Cancer, 6, 24–37.PubMed

70.

Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., et al. (2003). Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. The New England Journal of Medicine, 348, 203–213.PubMed

71.

Clevers, H. (2004). At the crossroads of inflammation and cancer. Cell, 118, 671–674.PubMed

72.

Aggarwal, B. B., Shishodia, S., Sandur, S. K., Pandey, M. K., & Sethi, G. (2006). Inflammation and cancer: How hot is the link? Biochemical Pharmacology, 72, 1605–1621.PubMed

73.

Seitz, C. S., Lin, Q., Deng, H., & Khavari, P. A. (1998). Alterations in NF-kappaB function in transgenic epithelial tissue demonstrate a growth inhibitory role for NF-kappaB. Proceedings of the National Academy of Sciences of the United States of America, 95, 2307–2312.PubMed

74.

Dajee, M., Lazarov, M., Zhang, J. Y., Cai, T., Green, C. L., et al. (2003). NF-kappaB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. Nature, 421, 639–643.PubMed

75.

Karin, M. (2009). NF-kappaB as a critical link between inflammation and cancer. Cold Spring Harbor Perspectives in Biology, 1, a000141.PubMed

76.

Kaipainen, A., Kieran, M. W., Huang, S., Butterfield, C., Bielenberg, D., et al. (2007). PPARalpha deficiency in inflammatory cells suppresses tumor growth. PLoS ONE, 2, e260.PubMed

77.

Panigrahy, D., Kaipainen, A., Kieran, M.W., Huang, S. (2008). PPARs: A Double-Edged Sword in Cancer Therapy? PPAR Res 2008: 350351.

78.

Ono, M. (2008). Molecular links between tumor angiogenesis and inflammation: Inflammatory stimuli of macrophages and cancer cells as targets for therapeutic strategy. Cancer Science, 99, 1501–1506.PubMed

79.

Salcedo, R., Zhang, X., Young, H. A., Michael, N., Wasserman, K., et al. (2003). Angiogenic effects of prostaglandin E2 are mediated by up-regulation of CXCR4 on human microvascular endothelial cells. Blood, 102, 1966–1977.PubMed

80.

Freedman, R. S., Wang, E., Voiculescu, S., Patenia, R., Bassett, R. L., Jr., et al. (2007). Comparative analysis of peritoneum and tumor eicosanoids and pathways in advanced ovarian cancer. Clinical Cancer Research, 13, 5736–5744.PubMed

81.

Ishizuka, T., Cheng, J., Singh, H., Vitto, M. D., Manthati, V. L., et al. (2008). 20-Hydroxyeicosatetraenoic acid stimulates nuclear factor-kappaB activation and the production of inflammatory cytokines in human endothelial cells. The Journal of Pharmacology and Experimental Therapeutics, 324, 103–110.PubMed

82.

Guo, A. M., Arbab, A. S., Falck, J. R., Chen, P., Edwards, P. A., et al. (2007). Activation of vascular endothelial growth factor through reactive oxygen species mediates 20-hydroxyeicosatetraenoic acid-induced endothelial cell proliferation. The Journal of Pharmacology and Experimental Therapeutics, 321, 18–27.PubMed

83.

Dhanasekaran, A., Bodiga, S., Gruenloh, S., Gao, Y., Dunn, L., et al. (2009). 20-HETE increases survival and decreases apoptosis in pulmonary arteries and pulmonary artery endothelial cells. American Journal of Physiology. Heart and Circulatory Physiology, 296, H777–H786.PubMed

84.

Chen, P., Guo, M., Wygle, D., Edwards, P. A., Falck, J. R., et al. (2005). Inhibitors of cytochrome P450 4A suppress angiogenic responses. The American Journal of Pathology, 166, 615–624.PubMed

85.

Ljubimov, A. V., & Grant, M. B. (2005). P450 in the angiogenesis affair: The unusual suspect. The American Journal of Pathology, 166, 341–344.PubMed

86.

Amaral, S. L., Maier, K. G., Schippers, D. N., Roman, R. J., & Greene, A. S. (2003). CYP4A metabolites of arachidonic acid and VEGF are mediators of skeletal muscle angiogenesis. American Journal of Physiology. Heart and Circulatory Physiology, 284, H1528–H1535.PubMed

87.

Sa, G., Murugesan, G., Jaye, M., Ivashchenko, Y., & Fox, P. L. (1995). Activation of cytosolic phospholipase A2 by basic fibroblast growth factor via a p42 mitogen-activated protein kinase-dependent phosphorylation pathway in endothelial cells. The Journal of Biological Chemistry, 270, 2360–2366.PubMed

88.

Jiang, M., Mezentsev, A., Kemp, R., Byun, K., Falck, J. R., et al. (2004). Smooth muscle-specific expression of CYP4A1 induces endothelial sprouting in renal arterial microvessels. Circulation Research, 94, 167–174.PubMed

89.

Miyata, N., Taniguchi, K., Seki, T., Ishimoto, T., Sato-Watanabe, M., et al. (2001). HET0016, a potent and selective inhibitor of 20-HETE synthesizing enzyme. British Journal of Pharmacology, 133, 325–329.PubMed

90.

Guo, M., Roman, R. J., Falck, J. R., Edwards, P. A., & Scicli, A. G. (2005). Human U251 glioma cell proliferation is suppressed by HET0016 [N-hydroxy-N’-(4-butyl-2-methylphenyl)formamidine], a selective inhibitor of CYP4A. The Journal of Pharmacology and Experimental Therapeutics, 315, 526–533.PubMed

91.

Jacobs, E. R., Zhu, D., Gruenloh, S., Lopez, B., & Medhora, M. (2006). VEGF-induced relaxation of pulmonary arteries is mediated by endothelial cytochrome P-450 hydroxylase. American Journal of Physiology. Lung Cellular and Molecular Physiology, 291, L369–L377.PubMed

92.

Guo, A. M., Sheng, J., Scicli, G. M., Arbab, A. S., Lehman, N. L., et al. (2008). Expression of CYP4A1 in U251 human glioma cell induces hyperproliferative phenotype in vitro and rapidly growing tumors in vivo. The Journal of Pharmacology and Experimental Therapeutics, 327, 10–19.PubMed

93.

Guo, M., Roman, R. J., Fenstermacher, J. D., Brown, S. L., Falck, J. R., et al. (2006). 9 L gliosarcoma cell proliferation and tumor growth in rats are suppressed by N-hydroxy-N’-(4-butyl-2-methylphenol) formamidine (HET0016), a selective inhibitor of CYP4A. The Journal of Pharmacology and Experimental Therapeutics, 317, 97–108.PubMed

94.

Alexanian, A., Rufanova, V. A., Miller, B., Flasch, A., Roman, R. J., et al. (2009). Down-regulation of 20-HETE synthesis and signaling inhibits renal adenocarcinoma cell proliferation and tumor growth. Anticancer Research, 29, 3819–3824.PubMed

95.

Nithipatikom, K., Isbell, M. A., See, W. A., & Campbell, W. B. (2006). Elevated 12- and 20-hydroxyeicosatetraenoic acid in urine of patients with prostatic diseases. Cancer Letters, 233, 219–225.PubMed

96.

Fleming, I. (2008). Vascular cytochrome p450 enzymes: Physiology and pathophysiology. Trends in Cardiovascular Medicine, 18, 20–25.PubMed

97.

Gross, G. J., Falck, J. R., Gross, E. R., Isbell, M., Moore, J., et al. (2005). Cytochrome P450 and arachidonic acid metabolites: Role in myocardial ischemia/reperfusion injury revisited. Cardiovascular Research, 68, 18–25.PubMed

98.

Chaudhary, K. R., Batchu, S. N., Das, D., Suresh, M. R., Falck, J. R., et al. (2009). Role of B-type natriuretic peptide in epoxyeicosatrienoic acid-mediated improved post-ischaemic recovery of heart contractile function. Cardiovascular Research, 83, 362–370.PubMed

99.

Simpkins, A. N., Rudic, R. D., Schreihofer, D. A., Roy, S., Manhiani, M., et al. (2009). Soluble epoxide inhibition is protective against cerebral ischemia via vascular and neural protection. The American Journal of Pathology, 174, 2086–2095.PubMed

100.

Zhang, C., & Harder, D. R. (2002). Cerebral capillary endothelial cell mitogenesis and morphogenesis induced by astrocytic epoxyeicosatrienoic acid. Stroke, 33, 2957–2964.PubMed

101.

Medhora, M., Daniels, J., Mundey, K., Fisslthaler, B., Busse, R., et al. (2003). Epoxygenase-driven angiogenesis in human lung microvascular endothelial cells. American Journal of Physiology. Heart and Circulatory Physiology, 284, H215–H224.PubMed

102.

Ausprunk, D. H., & Folkman, J. (1977). Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. Microvascular Research, 14, 53–61.PubMed

103.

Wang, Y., Wei, X., Xiao, X., Hui, R., Card, J. W., et al. (2005). Arachidonic acid epoxygenase metabolites stimulate endothelial cell growth and angiogenesis via mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways. The Journal of Pharmacology and Experimental Therapeutics, 314, 522–532.PubMed

104.

Ribatti, D., Vacca, A., Roncali, L., & Dammacco, F. (2000). The chick embryo chorioallantoic membrane as a model for in vivo research on antiangiogenesis. Current Pharmaceutical Biotechnology, 1, 73–82.PubMed

105.

Michaelis, U. R., Fisslthaler, B., Medhora, M., Harder, D., Fleming, I., et al. (2003). Cytochrome P450 2 C9-derived epoxyeicosatrienoic acids induce angiogenesis via cross-talk with the epidermal growth factor receptor (EGFR). The FASEB Journal, 17, 770–772.PubMed

106.

Yan, G., Chen, S., You, B., & Sun, J. (2008). Activation of sphingosine kinase-1 mediates induction of endothelial cell proliferation and angiogenesis by epoxyeicosatrienoic acids. Cardiovascular Research, 78, 308–314.PubMed

107.

Webler, A. C., Popp, R., Korff, T., Michaelis, U. R., Urbich, C., et al. (2008). Cytochrome P450 2 C9-induced angiogenesis is dependent on EphB4. Arteriosclerosis, Thrombosis, and Vascular Biology, 28, 1123–1129.PubMed

108.

Zhang, B., Cao, H., & Rao, G. N. (2006). Fibroblast growth factor-2 is a downstream mediator of phosphatidylinositol 3-kinase-Akt signaling in 14, 15-epoxyeicosatrienoic acid-induced angiogenesis. The Journal of Biological Chemistry, 281, 905–914.PubMed

109.

Cheranov, S. Y., Karpurapu, M., Wang, D., Zhang, B., Venema, R. C., et al. (2008). An essential role for SRC-activated STAT-3 in 14, 15-EET-induced VEGF expression and angiogenesis. Blood, 111, 5581–5591.PubMed

110.

Yang, S., Lin, L., Chen, J. X., Lee, C. R., Seubert, J. M., et al. (2007). Cytochrome P-450 epoxygenases protect endothelial cells from apoptosis induced by tumor necrosis factor-alpha via MAPK and PI3K/Akt signaling pathways. American Journal of Physiology. Heart and Circulatory Physiology, 293, H142–H151.PubMed

111.

Tsuzuki, Y., Fukumura, D., Oosthuyse, B., Koike, C., Carmeliet, P., et al. (2000). Vascular endothelial growth factor (VEGF) modulation by targeting hypoxia-inducible factor-1alpha– > hypoxia response element– > VEGF cascade differentially regulates vascular response and growth rate in tumors. Cancer Research, 60, 6248–6252.PubMed

112.

Michaelis, U. R., Fisslthaler, B., Barbosa-Sicard, E., Falck, J. R., Fleming, I., et al. (2005). Cytochrome P450 epoxygenases 2 C8 and 2 C9 are implicated in hypoxia-induced endothelial cell migration and angiogenesis. Journal of Cell Science, 118, 5489–5498.PubMed

113.

Earley, S., Pastuszyn, A., & Walker, B. R. (2003). Cytochrome p-450 epoxygenase products contribute to attenuated vasoconstriction after chronic hypoxia. American Journal of Physiology. Heart and Circulatory Physiology, 285, H127–H136.PubMed

114.

Suzuki, S., Oguro, A., Osada-Oka, M., Funae, Y., & Imaoka, S. (2008). Epoxyeicosatrienoic acids and/or their metabolites promote hypoxic response of cells. Journal of Pharmacological Sciences, 108, 79–88.PubMed

115.

Webler, A. C., Michaelis, U. R., Popp, R., Barbosa-Sicard, E., Murugan, A., et al. (2008). Epoxyeicosatrienoic acids are part of the VEGF-activated signaling cascade leading to angiogenesis. American Journal of Physiology. Cell Physiology, 295, C1292–C1301.PubMed

116.

Yang, S., Wei, S., Pozzi, A., & Capdevila, J. H. (2009). The arachidonic acid epoxygenase is a component of the signaling mechanisms responsible for VEGF-stimulated angiogenesis. Archives of Biochemistry and Biophysics, 489, 82–91.PubMed

117.

Dunn, L. K., Gruenloh, S. K., Dunn, B. E., Reddy, D. S., Falck, J. R., et al. (2005). Chick chorioallantoic membrane as an in vivo model to study vasoreactivity: Characterization of development-dependent hyperemia induced by epoxyeicosatrienoic acids (EETs). The Anatomical Record. Part A: Discoveries in Molecular, Cellular, and Evolutionary Biology, 285, 771–780.

118.

Harris, R. C., Homma, T., Jacobson, H. R., & Capdevila, J. (1990). Epoxyeicosatrienoic acids activate Na+/H+exchange and are mitogenic in cultured rat glomerular mesangial cells. Journal of Cellular Physiology, 144, 429–437.PubMed

119.

Sellmayer, A., Uedelhoven, W. M., Weber, P. C., & Bonventre, J. V. (1991). Endogenous non-cyclooxygenase metabolites of arachidonic acid modulate growth and mRNA levels of immediate-early response genes in rat mesangial cells. The Journal of Biological Chemistry, 266, 3800–3807.PubMed

120.

Jiang, J. G., Chen, C. L., Card, J. W., Yang, S., Chen, J. X., et al. (2005). Cytochrome P450 2 J2 promotes the neoplastic phenotype of carcinoma cells and is up-regulated in human tumors. Cancer Research, 65, 4707–4715.PubMed

121.

Jiang, J. G., Ning, Y. G., Chen, C., Ma, D., Liu, Z. J., et al. (2007). Cytochrome p450 epoxygenase promotes human cancer metastasis. Cancer Research, 67, 6665–6674.PubMed

122.

Chen, C., Li, G., Liao, W., Wu, J., Liu, L., et al. (2009). Selective inhibitors of CYP2J2 related to terfenadine exhibit strong activity against human cancers in vitro and in vivo. The Journal of Pharmacology and Experimental Therapeutics, 329, 908–918.PubMed

123.

Pozzi, A., Ibanez, M. R., Gatica, A. E., Yang, S., Wei, S., et al. (2007). Peroxisomal proliferator-activated receptor-alpha-dependent inhibition of endothelial cell proliferation and tumorigenesis. The Journal of Biological Chemistry, 282, 17685–17695.PubMed

124.

Zagorac, D., Jakovcevic, D., Gebremedhin, D., & Harder, D. R. (2008). Antiangiogenic effect of inhibitors of cytochrome P450 on rats with glioblastoma multiforme. Journal of Cerebral Blood Flow and Metabolism, 28, 1431–1439.PubMed

125.

Nithipatikom, K., Brody, D.M., Tang, A.T., Manthati, V.L., Falck, J.R., et al. (2010). Inhibition of carcinoma cell motility by epoxyeicosatrienoic acid (EET) antagonists. Cancer Sci.

126.

Pozzi, A., Popescu, V., Yang, S., Mei, S., Shi, M., et al. (2010). The anti-tumorigenic properties of peroxisomal proliferator-activated receptor alpha are arachidonic acid epoxygenase-mediated. The Journal of Biological Chemistry, 285, 12840–12850.PubMed

127.

Enayetallah, A. E., French, R. A., & Grant, D. F. (2006). Distribution of soluble epoxide hydrolase, cytochrome P450 2 C8, 2 C9 and 2 J2 in human malignant neoplasms. Journal of Molecular Histology, 37, 133–141.PubMed

128.

Leclerc, J., Tournel, G., Courcot-Ngoubo Ngangue, E., Pottier, N., Lafitte, J. J., et al. (2010). Profiling gene expression of whole cytochrome P450 superfamily in human bronchial and peripheral lung tissues: Differential expression in non-small cell lung cancers. Biochimie, 92, 292–306.PubMed

129.

Yang, M. D., Wu, C. C., Chiou, S. H., Chiu, C. F., Lin, T. Y., et al. (2003). Reduction of dihydrodiol dehydrogenase expression in resected hepatocellular carcinoma. Oncology Reports, 10, 271–276.PubMed

130.

Roques, M., Bagrel, D., Magdalou, J., & Siest, G. (1991). Expression of arylhydrocarbon hydroxylase, epoxide hydrolases, glutathione S-transferase and UDP-glucuronosyltransferases in H5-6 hepatoma cells. General Pharmacology, 22, 677–684.PubMed

131.

Rahman, A., Korzekwa, K. R., Grogan, J., Gonzalez, F. J., & Harris, J. W. (1994). Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8. Cancer Research, 54, 5543–5546.PubMed

132.

Jernstrom, H., Bageman, E., Rose, C., Jonsson, P. E., & Ingvar, C. (2009). CYP2C8 and CYP2C9 polymorphisms in relation to tumour characteristics and early breast cancer related events among 652 breast cancer patients. British Journal of Cancer, 101, 1817–1823.PubMed

133.

Dai, D., Zeldin, D. C., Blaisdell, J. A., Chanas, B., Coulter, S. J., et al. (2001). Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics, 11, 597–607.PubMed

134.

Isomura, Y., Yamaji, Y., Ohta, M., Seto, M., Asaoka, Y., et al. (2010). A genetic polymorphism of CYP2C19 is associated with susceptibility to biliary tract cancer. J Gastroenterol.

Title: Cytochrome P450-derived eicosanoids: the neglected pathway in cancer
Authors: Dipak Panigrahy
Arja Kaipainen
Emily R. Greene
Sui Huang
Publication date: 01-12-2010
Publisher: Springer US
Published in: Cancer and Metastasis Reviews / Issue 4/2010
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-010-9264-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2010

Minimizing early relapse and maximizing treatment outcomes in hormone-sensitive postmenopausal breast cancer: efficacy review of AI trials

CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression

Obesity and breast cancer: status of leptin and adiponectin in pathological processes

Expression of tenascin-C and its isoforms in the breast

Regulatory T cells and breast cancer: implications for immunopathogenesis

Feedback regulation of proteasome gene expression and its implications in cancer therapy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer